BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
18.23
+0.08 (0.44%)
Jun 2, 2023, 12:09 PM EDT - Market open
BioXcel Therapeutics Stock Forecast
Stock Price Forecast
According to 6 stock analysts, the average 12-month stock price forecast for BTAI stock stock is $45.83, which predicts an increase of 151.40%. The lowest target is 22 and the highest is 76. On average, analysts rate BTAI stock stock as a strong buy.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BTAI stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 6 | 6 | 6 |
Financial Forecast
Revenue This Year
7.40M
from 375.00K
Increased by
1,872.27%
Revenue Next Year
58.69M
from 7.40M
Increased by
693.52%
EPS This Year
-6.43
from -5.92
EPS Next Year
-4.87
from -6.43
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 375.00K | 7.40M | 58.69M | 147.87M | 388.72M | 546.56M |
| Revenue Growth | - | - | - | - | - | 1,872.27% | 693.52% | 151.96% | 162.88% | 40.61% |
| EPS | -1.32 | -2.02 | -3.79 | -4.05 | -5.92 | -6.43 | -4.87 | -2.57 | 3.52 | 7.40 |
| EPS Growth | - | - | - | - | - | - | - | - | - | 110.29% |
| No. Analysts | - | - | - | - | - | 13 | 13 | 11 | 4 | 4 |
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 15.8M | 199.5M | 548.1M | 1.0B | 1.2B |
| Avg | 7.4M | 58.7M | 147.9M | 388.7M | 546.6M |
| Low | 2.9M | 17.6M | 29.8M | 124.3M | 234.9M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 4,100.0%
| 2,597.4%
| 833.9%
| 581.0%
| 221.1%
|
| Avg | 1,872.3%
| 693.5%
| 152.0%
| 162.9%
| 40.6%
|
| Low | 684.0%
| 138.5%
| -49.2%
| -16.0%
| -39.6%
|
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -5.25 | -1.29 | 4.82 | 4.48 | 9.47 |
| Avg | -6.43 | -4.87 | -2.57 | 3.52 | 7.40 |
| Low | -7.39 | -6.65 | -5.65 | 2.58 | 5.38 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | - | 169.1%
|
| Avg | - | - | - | - | 110.3%
|
| Low | - | - | - | - | 52.9%
|
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.